New horizon of radiopharmaceuticals in management of neuroendocrine tumors

Adeel Haq, Sampanna Rayamajhi, Maria Rosana Ponisio, Vikas Prasad

Research output: Contribution to journalReview articlepeer-review


Neuroendocrine neoplasms are rare and heterogenous group of tumors with varying degrees of clinical presentations and involvement of multiple organ systems in the body. In the modern clinical practice somatostatin receptor molecular imaging and targeted radioligand therapy plays a vital role in the diagnosis and management of the disease. Several new and promising radiotracers for NET imaging and theranostics, belonging to various groups and classes are being studied and investigated. This exponential growth of radiotracers poses concerns about the indication, clinical benefit, and safety profile of the agents. We discuss the basis behind these radiotracers clinical use, receptor targeting and intra and inter tumor heterogeneity. Furthermore, role of dual tracer imaging, combination therapy and potential applications of dosimetry in predicting treatment outcome and safety profile is reviewed. Individualized precision medicine with better tumor characterization, maximum therapeutic benefit and minimum toxicity is the way forward for future medicine.

Original languageEnglish
Article number101797
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
StateAccepted/In press - 2023


  • PET/CT
  • neuroendocrine tumor
  • peptide receptor radionuclide therapy
  • radiotracers
  • renal toxicity
  • somatostatin receptors
  • theranostics
  • tumor heterogeneity


Dive into the research topics of 'New horizon of radiopharmaceuticals in management of neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this